The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Nanoparticulate Delivery Systems for Antiviral Drugs
Abstract
Nanomedicine opens new therapeutic avenues for attacking viral diseases and for improving treatment success rates. Nanoparticulate-based systems might change the release kinetics of antivirals, increase their bioavailability, improve their efficacy, restrict adverse drug side effects and reduce treatment costs. Moreover, they could permit the delivery of antiviral drugs to specific target sites and viral reservoirs in the body. These features are particularly relevant in viral diseases where high drug doses are needed, drugs are expensive and the success of a therapy is associated with a patient's adherence to the administration protocol. This review presents the current status in the emerging area of nanoparticulate delivery systems in antiviral therapy, providing their definition and description, and highlighting some peculiar features. The paper closes with a discussion on the future challenges that must be addressed before the potential of nanotechnology can be translated into safe and effective antiviral formulations for clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxic potential of materials at the nanolevel
Nel, A., Xia, T., Mädler, L., & Li, N. (2006) · Science · doi:10.1126/science.1114397 · Cited by 9,324
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910
Multifunctional and stimuli-sensitive pharmaceutical nanocarriers
Torchilin, V. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.026 · Cited by 583
Schäfer, V., von Briesen, H., Andreesen, R., Steffan, A.-M., Royer, C., Tröster, S., Kreuter, J., & Rübsamen-Waigmann, H. (1992) · Pharmaceutical Research · doi:10.1023/a:1015852732512 · Cited by 146
The potential of RNA interference-based therapies for viral infections
Huang, D. D. (2008) · Current HIV/AIDS Reports · doi:10.1007/s11904-008-0006-4 · Cited by 20
Cited by
Current applications of nanoparticles in infectious diseases
Zazo, H., Colino, C. I., & Lanao, J. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.008 · Cited by 434
Liposomes: Clinical Applications and Potential for Image-Guided Drug Delivery
Lamichhane, N., Udayakumar, T., D’Souza, W., Simone II, C., Raghavan, S., Polf, J., & Mahmood, J. (2018) · Molecules · doi:10.3390/molecules23020288 · Cited by 303
Wuttke, S., Lismont, M., Escudero, A., Rungtaweevoranit, B., & Parak, W. J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.01.025 · Cited by 286
An overview of functional nanoparticles as novel emerging antiviral therapeutic agents
Chen, L., & Liang, J. (2020) · Materials Science and Engineering: C · doi:10.1016/j.msec.2020.110924 · Cited by 255
Yang, K.-C., Lin, J.-C., Tsai, H.-H., Hsu, C.-Y., Shih, V., & Hu, C.-M. J. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00965-y · Cited by 39
Metadata
- Authors
- Lembo, D., & Cavalli, R.
- Venue
- Antiviral Chemistry and Chemotherapy
- Publisher
- SAGE Publications
- Published
- 2010-12
- Volume
- 21
- Issue
- 2
- Pages
- 53-70
- ISSN
- 0956-3202 (ISSN-L)
- 2040-2066
- OpenAlex
- W1968534837
- Cited by
- 203
- References
- 7
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.